Claus Kremoser
Affimed Therapeutics (Germany)(DE)
Publications by Year
Research Areas
Drug Transport and Resistance Mechanisms, Liver Disease Diagnosis and Treatment, Cholesterol and Lipid Metabolism, Estrogen and related hormone effects, Liver Diseases and Immunity
Most-Cited Works
- → In vitro guidance of retinal ganglion cell axons by RAGS, a 25 kDa tectal protein related to ligands for Eph receptor tyrosine kinases(1995)852 cited
- → Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis(2017)317 cited
- → Identification of Farnesoid X Receptor β as a Novel Mammalian Nuclear Receptor Sensing Lanosterol(2003)176 cited
- → The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction(2016)168 cited
- → Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice(2017)138 cited
- → Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice(2012)98 cited
- → A Novel Principle for Partial Agonism of Liver X Receptor Ligands(2005)92 cited
- → FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model(2012)83 cited
- → FXR agonists for NASH: How are they different and what difference do they make?(2021)74 cited
- → Nonsteroidal FXR Ligands: Current Status and Clinical Applications(2019)73 cited